nVerses Capital’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-17,749
Closed -$259K – 211
2026
Q2
$259K Buy
+17,749
New +$315K 0.4% 95

Other funds holding SMMT

nVerses Capital's SMMT Position: Q3 2026 in Review

nVerses Capital sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 17,749 shares — an estimated $259K sold.

nVerses Capital first reported a position in SMMT in Q2 2026 and held it in 1 quarter. The position peaked at $259K in Q2 2026. 295 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • nVerses Capital reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
  • nVerses Capital sold 17,749 Summit Therapeutics shares in Q3 2026, an estimated $259K.
  • nVerses Capital first reported a position in Summit Therapeutics in Q2 2026 and held it in 1 quarter.
  • nVerses Capital's Summit Therapeutics position peaked at $259K in Q2 2026.
  • 295 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on nVerses Capital's 13F filing for Q3 2026.